News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology

March 3, 2017

Barcelona (Catalonia, Spain), March 7, 2017. Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the sponsorship of the of 37th National Meeting of the Spanish Society of Pharmacology (SEF). The Meeting will be held in Barcelona from Sunday 18th to Wednesday 21th June 2017, with the British Pharmacological Society (BPS) as the main guest (http://www.sef2017.com).
 
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
 
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.

LATEST NEWS

07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
05.02.2014

News

ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
19.02.2013

News

Ability Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits